Navigation Links
Amsterdam Molecular Therapeutics Reports Half-Year Results 2011
Date:8/24/2011

AMSTERDAM, The Netherlands, August 25, 2011 /PRNewswire/ --

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today reported its results for the first half year of 2011.

Highlights

  • Glybera®:
    • Data showing Glybera produces significant reduction in risk of pancreatitis in LPLD patients presented at European Atherosclerosis Society Meeting
    • CHMP does not consider Glybera approvable at this time
    • Chylomicrons now validated as biomarker for Glybera efficacy; data presented at American Society of Gene and Cell Therapy annual meeting
    • AMT generating further chylomicron data from existing treated patients to support re-examination process
    • Submitted for re-examination, outcome expected before end 2011
  • Collaboration with Institut Pasteur-led Consortium to develop Sanfilippo B gene therapy product for cGMP manufactured material; worth up to € 1.8 million to AMT
  • € 1.1 million funding for Acute Intermittent Porphyria gene therapy product as part of EU Consortium
  • Grant from Dutch Parents Association for Duchenne Muscular Dystrophy gene therapy
  • Appointment of Dr. Carlos R. Camozzi as Chief Medical Officer
  • Key financial figures in line with guidance
  • Cash & cash equivalents of € 9.1 million at June 30, 2011, in line with budget

"We have moved quickly and have already filed an application for re-examination of Glybera, after the initial disappointment with the CHMP opinion in June. We are continuing to collect more data to show that there is a long-term reduction in the incidence of pancreatitis in treated patients.  We will be able to generate the additional data required from the existing treated patients, and the data will come from a trial which we had already pla
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
2. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
4. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
5. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
6. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
7. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
8. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
9. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
10. Molecular sleuths track evolution through the ribosome
11. VisEn Announces Commercial Launch of IntegriSenseTM Fluorescence Molecular Imaging Agent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 18, 2014 Research and Markets ... Chinese Stem Cell Industry Report, 2014-2017" report to ... biological cells that can differentiate into specialized cells and ... Stem cell therapy can be applied to treatment of ... nervous system diseases, damage or lesion of liver, kidney ...
(Date:9/18/2014)... -- Research and Markets has announced the ... 2014" report to their offering. ... professional and in-depth study on the current state of ... provides a basic overview of the industry including definitions, ... market analysis is provided for the international markets including ...
(Date:9/18/2014)... 2014 Leatherwood Plastics has selected ... to stay competitive in the semiconductor, clean room ... ultimately impact product quality and productivity, according to ... Established in 1980 in Lewisville, TX, Leatherwood ... have left the business. Much of Leatherwood’s equipment ...
(Date:9/18/2014)... , Sept. 18, 2014  MEI Pharma, Inc. (Nasdaq: ... clinical development of novel therapies for cancer, announced today that ... Officer, will present at BioCentury,s NewsMakers in the Biotech ... a.m. Eastern time from the Millennium Broadway Hotel & Conference ... webcast of the presentation can be accessed at www.meipharma.com ...
Breaking Biology Technology:Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2MEI Pharma To Present At BioCentury's NewsMakers Conference 2MEI Pharma To Present At BioCentury's NewsMakers Conference 3
... SOMERSET, N.J., June 9 Alfacell Corporation,(Nasdaq: ACEL ... quarter,of fiscal 2008., The company recorded a net ... diluted common share, for the third fiscal quarter ended,April ... million, or $0.04,per basic and diluted common share, for ...
... Limited (LSE: SHP,Nasdaq: SHPGY), the global specialty biopharmaceutical ... lots of the ADHD patch DAYTRANA (lots,2750211 and ... DAYTRANA,patches do not meet their release liner removal ... have difficulties removing the,liners. This voluntary recall is ...
... 9 Amira Pharmaceuticals, a small,molecule pharmaceutical company ... treat inflammatory diseases, announced the hiring of Michael,V. ... Swanson has over 30 years of experience in ... in life sciences and specialty,pharmaceutical companies. Prior to ...
Cached Biology Technology:Alfacell Reports Financial Results for Third Quarter of Fiscal 2008 2Alfacell Reports Financial Results for Third Quarter of Fiscal 2008 3Alfacell Reports Financial Results for Third Quarter of Fiscal 2008 4Alfacell Reports Financial Results for Third Quarter of Fiscal 2008 5Alfacell Reports Financial Results for Third Quarter of Fiscal 2008 6Non-Safety-Related Voluntary Recall of a Limited Portion of DAYTRANA(TM) (Methylphenidate Transdermal System) Patches Announced 2Non-Safety-Related Voluntary Recall of a Limited Portion of DAYTRANA(TM) (Methylphenidate Transdermal System) Patches Announced 3Non-Safety-Related Voluntary Recall of a Limited Portion of DAYTRANA(TM) (Methylphenidate Transdermal System) Patches Announced 4Amira Pharmaceuticals Hires Industry Veteran for CFO Position 2
(Date:9/18/2014)... have developed a unique method to use microbes buried ... areas. , The first microbe-powered, self-sustaining wastewater treatment ... to clean up waste from large farming operations and ... Professor Haluk Beyenal and graduate student Timothy Ewing in ... system in the online edition of Journal of ...
(Date:9/18/2014)... that can operate inside the bore of an MRI ... biomedical research partnership program at Brigham and Women,s Hospital ... robot, in conjunction with real-time MRI images, can make ... less discomforting for the patient. The novel system also ... greater precision. , Developed by a team of robotics ...
(Date:9/18/2014)... acquire and creatively manipulate spoken language is unique to ... 6 million years of human evolution to make this ... candidate gene we now have," says Wolfgang Enard, Professor ... efforts to understand the molecular biological basis of language ... results of his latest study, undertaken in collaboration with ...
Breaking Biology News(10 mins):Researchers develop unique waste cleanup for rural areas 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3
... University is proving its potential to impact global health. ... journal PLoS ONE , Rice alumnus Andrew Miller ... which costs $240, stacks up nicely against devices that ... of tuberculosis. Miller and colleagues at The Methodist ...
... not recognized as an animal until the 19th century, is ... have their genome sequenced. In a paper appearing in ... a team of researchers led by Daniel Rokhsar of the ... Genome Institute (JGI), report the draft genome sequence of the ...
... How well do you understand life in your own backyard? Cities ... aren,t visitors; they are an integral component, like trees in a ... the Earth,s people live in cities and the amount of paved ... Ohio, shouldn,t our sciences thrive in the city? Urban Ecosystem ...
Cached Biology News:Compact microscope a marvel 2Compact microscope a marvel 3Genome of ancient sponge reveals origins of first animals, cancer 2Genome of ancient sponge reveals origins of first animals, cancer 3Genome of ancient sponge reveals origins of first animals, cancer 4The real urban jungle 2
...
The piston kit includes 2 pistons to service one F10 pump of a BioLogic DuoFlow workstation....
BD BioCoat Poly-D-Lysine/Laminin 100 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of poly-D-lysine and laminin....
BD BioCoat BD MatrigelTM Matrix 100 mm Culture Dishes for hepatocytes, tissue-culture treated polystyrene with a uniform application of MATRIGEL Matrix....
Biology Products: